Does Adding PEMF to a Treatment You Already Give Improve the Result?
five controlled studies, two answers

September 2026 · 9 min read · Clinical Evidence Review

Bottom line: Five controlled studies have tested directly whether adding a pulsed electromagnetic field to a treatment already being delivered improves the result. In three it did; in two it did not. The finding that matters most to a clinic already running a shockwave device: adding PEMF to shockwave in calcaneal spur produced significantly lower pain and better foot function than shockwave alone, at end of treatment and at three months (PubMed 38310424) — and that is a PEMF device, not EMTT. A comparable shoulder result — 86 patients with rotator cuff tendinopathy — found that shockwave combined with an electromagnetic field outperformed shockwave combined with a sham field at 24 weeks (PubMed 30183430). Note carefully: the device tested there is EMTT — a high-intensity electromagnetic field, not a standard PEMF system. These are two different technologies and their figures are not automatically transferable. The variable separating the successful trials from the unsuccessful ones is not "synergy" but dose, length of follow-up, and quality of blinding.

Why "Does It Work" and "Is It Worth Adding" Are Two Separate Questions

PEMF is a non-invasive treatment that delivers a low-intensity pulsed electromagnetic field through tissue, aiming to influence cellular processes such as calcium flow across the cell membrane, cellular energy production and the local inflammatory response. It has been in rehabilitative use for more than four decades.

A trial comparing PEMF against a sham answers the first question. A trial comparing an existing treatment plus PEMF against that same existing treatment plus a sham answers the second — and it is far harder, because the base treatment is already improving both groups. This is why a combination trial can fail even when the technology itself works: if the exercise programme alone takes the patient to the ceiling, no headroom remains for the addition to prove itself. That distinction is the key to reading everything below.

Does Adding PEMF to an Exercise Programme Improve the Outcome?

In the best double-blind trial that exists — yes, and the gap widens over time. A double-blind, placebo-controlled randomized trial from the University of Castilla-La Mancha in Toledo, published in January 2026, enrolled 60 participants (83 knees) with knee osteoarthritis. All received the same exercise programme and were randomized to add active PEMF, microwave therapy, or sham PEMF. At four months the PEMF group reported lower pain than the sham group on the WOMAC (mean difference 3.2 points, p=0.028), less stiffness at all three measurement points, and an improvement on the timed up-and-go test found in no other group (PubMed 39868691).

Two other trials did not find that advantage. At Jordan University of Science and Technology, 34 patients with knee osteoarthritis were randomized to 24 sessions of progressive resistance exercise with or without PEMF; no significant between-group difference was found on any measure — not pain, not function, not walking speed — at any timepoint out to six months (PubMed 37718773). In Hong Kong, 65 patients with Achilles tendinopathy were randomized to active or sham PEMF alongside an eccentric exercise programme; both groups improved and the improvement held to 26 weeks, but the trial demonstrated no separation between them (PubMed 41651914). Both research groups attributed this to dose rather than to efficacy, and called for optimal field parameters to be established.

What Happened When an Electromagnetic Field Was Combined With Shockwave?

This is where the strongest positive result was found, and it is particularly relevant to clinics already operating a shockwave device. A randomized controlled trial of 86 patients with rotator cuff tendinopathy assigned participants to three shockwave sessions combined with eight sessions of high-intensity electromagnetic field therapy (EMTT), or to those same three shockwave sessions combined with sham EMTT. Both groups improved significantly in pain and function — but the combination group showed a significantly greater reduction in pain on the visual analogue scale at 24 weeks, alongside a significant improvement in the Constant-Murley shoulder function score (PubMed 30183430). The trial was run at orthopaedic centres in Kiel and Munich with tendon researchers from London.

Two caveats must be stated alongside that number. First, EMTT is a high-intensity electromagnetic field technology and is not identical to a standard rehabilitative PEMF system — the two share a physical description, not a protocol, and results cannot be moved between them automatically. Second, a 2026 double-blind EMTT trial examining the technology as a standalone treatment in 126 patients (80 mT, 8 Hz, 10,000 pulses per session) reported lower pain than sham at week 12 (2.2 vs 4.2, p<0.001) — but one of its authors declares a lecture fee from the device manufacturer, and a shared senior author appears on both trials (PubMed 41313312). This does not invalidate the findings, but it does mean the EMTT evidence base is narrow and close to the manufacturer.

Is There a Study Testing PEMF Itself — Not EMTT — Added to Shockwave?

Yes, and in it the addition improved every measure recorded. A controlled study from Adana City Training and Research Hospital and Çukurova University in Turkey examined 75 patients with calcaneal spurs: 35 received shockwave alone and 40 received shockwave plus PEMF. Both groups improved against baseline, but between the groups the combination arm showed significantly lower pain (VAS) and Foot Function Index scores — pain, disability and activity limitation — both at the end of treatment and at the three-month follow-up, p<0.001 on every measure (PubMed 38310424, Archives of Iranian Medicine 2023).

Why it matters, and what must be said alongside it. Its significance for a clinic is that this is a PEMF device rather than EMTT — the first time the shockwave pairing has been measured using the technology rehabilitation systems actually deliver, rather than a neighbouring one. The limitation belongs in the same breath: this is a retrospective study built from medical records, not a randomised or blinded trial. Patients were not allocated at random but according to the treatment recommended to them, so a pre-existing difference between the groups cannot be excluded. The authors themselves conclude that further studies are needed. It is good evidence of direction, not proof of effect size.

Why Did Two Trials Find an Advantage and Two Did Not?

The difference is not "synergy" — it is dose, length of measurement, and quality of blinding. Three methodological differences separate the positive trials from the negative ones, and each is controllable in a clinic:

1. Length of follow-up. In both positive trials the between-group difference appeared or widened at 24 weeks and at four months, not at the end of the treatment series. A trial measured mainly in the short term may miss precisely the window in which the addition expresses itself.
2. Quality of blinding. The Jordanian trial was single-blind with no sham arm; the other three included a genuine sham arm. Without a sham arm the comparison is made against no treatment rather than against the same therapeutic ritual without the field itself.
3. Dose. Both research groups that obtained a negative result phrased their conclusion identically — the optimal field parameters need to be determined. Neither concluded that the technology is without value.

The wider context supports that caution: a Cochrane review of electrotherapy modalities in adhesive capsulitis, covering 19 trials and 1,249 participants, concluded that it could not be determined whether adding PEMF to exercise is effective, on very low quality evidence — and noted explicitly that at the time of publication no trial had compared an electrotherapy modality plus manual therapy and exercise against manual therapy and exercise alone (PubMed 25271097). The trials above are part of the answer built since.

Comparison: The Five Studies That Tested Combination Directly

A row that does not appear in the table, and that defines the limits of this page: there is not one randomized trial anywhere testing PEMF combined with acupuncture. A literature search returns sources on each method separately, never on the pairing — so any claim of an advantage for that particular combination is mechanistic reasoning, not a measured finding. The same is true of several other pairings common in clinical practice.

So When Might Adding PEMF Actually Be Relevant?

When the existing treatment has reached a plateau, and the condition is one of those that has been tested. Three scenarios are supported by the evidence above, and one is not:

• Knee osteoarthritis alongside a structured exercise programme — the only pairing with a double-blind trial showing a sustained advantage.
• Shoulder tendinopathy in a clinic already operating shockwave — here a sham arm exists and the difference was measured at 24 weeks.
• Joint and soft-tissue pain not responding to routine care — a 2025 multi-centre RCT across five orthopaedic clinics, 91 participants, found a 36% pain reduction versus 10% with routine care and a 55% drop in medication use (PMC11914662).
• When not: as a replacement for a treatment that is already working, and as a reason to defer a recommended investigation or surgery. The combination has been tested as an addition only, and in two of the five studies it added nothing.

Clinical Implementation: Building a Combination Protocol You Can Defend

The protocol follows directly from the three variables that separated the trials. Four practical steps:

1. Measure before you add. A baseline score on a validated instrument — WOMAC for the knee, Constant-Murley for the shoulder, VAS for pain. Without a baseline there is no way to know whether the addition did anything, and taking one is exactly what the positive trials did.
2. Do not conclude at the end of the series. In both positive trials the difference was measured at 24 weeks and at four months. Set a follow-up measurement point in that range and present it to the patient in advance, so the expectation matches the data.
3. Keep the existing treatment unchanged. In all five studies the base treatment — exercise or shockwave — was delivered in full to both groups. An addition that arrives at the cost of shortening the exercise programme is not what was tested.
4. Document the field parameters. Intensity, frequency and pulses per session. Both research groups that obtained a negative result attributed it to dose; without documentation you cannot know which side of that line you are on.

From Field Experience Across the PainFree Network

This section describes operational observations from the field and is not trial results. Three points recur whenever a clinic adds a system alongside an existing treatment:

• Expectation breaks in the first two weeks. A patient who hears "addition" and sees no immediate change tends to stop before the measurement point at which the trials found any difference at all. The opening conversation that sets out the real timeline is what prevents drop-out.
• Intake is where contraindications are caught. Active electronic implants, pregnancy and active malignancy in the treatment area are asked on a written form, not verbally during a session.
• A combination that is not documented is forgotten. Clinics that record intensity, frequency and duration for every session are the only ones able to say afterwards what worked and for whom.

What This Means for Clinic Owners and Investors

The commercial question behind this article is narrower than "does PEMF work": it is whether a second modality earns its place beside equipment a clinic already owns. The evidence says it does in some pairings and not in others, and that the deciding factors are dose, follow-up length and honest measurement — all of which are inside the operator's control. 70+ Israeli clinics serving a population of 9M — now expanding to the Philippines have added the system, most of them alongside methods and equipment they already had rather than in place of them. The system runs hands-free, so the therapist is not tied to the bed for the session and the addition runs in parallel with existing chair time rather than competing for it. In the Philippines market, a treatment session in this category is typically priced at ₱1,500–₱2,500. The clinics that succeed with a combination protocol are distinguished not by the device but by the measurement discipline in front of it.

Frequently Asked Questions

Does combining PEMF with physiotherapy work better than physiotherapy alone?
Sometimes — it depends on the pairing and the dose. Of five controlled studies testing this directly, the combination was superior in three and no different in two. The double-blind knee trial found a 3.2-point WOMAC advantage at four months (PubMed 39868691), while the Hong Kong tendon trial demonstrated no separation between groups.

Can magnetic field therapy be combined with shockwave in the same series?
Yes, and this is the pairing with the strongest positive result. In a randomized trial of 86 patients with shoulder tendinopathy, shockwave combined with EMTT produced a significantly greater pain reduction than shockwave with a sham magnetic treatment at 24 weeks (PubMed 30183430). Note that EMTT is a high-intensity device and is not identical to a standard PEMF system.

How long should it take to see a difference from the combination?
Months, not sessions. In both trials that found an advantage, the between-group difference was measured at 24 weeks and at four months from the start of treatment — not at the end of the session series. Expecting an immediate change does not match what was measured, and it is the most common reason patients stop early.

Does combining PEMF with acupuncture give better results?
This has never been measured. There is no randomized trial in the medical literature testing that pairing. Evidence exists for each method separately, but a claim of advantage for the combination is a mechanistic explanation rather than a finding. That distinction is what separates reliable information from marketing.

Does the addition require shortening the existing physiotherapy?
No, and in all five studies it was not shortened. The base treatment was delivered in full to both groups and the electromagnetic field was added on top. Using PEMF at the expense of the exercise programme is not the protocol that was tested, and there is no data on its outcomes.

Who is the combination not suitable for?
Anyone with an active electronic implant, women who are pregnant, and patients with active malignancy in the treatment area. These are absolute contraindications. Nearby metal implants, epilepsy and hyperthyroidism require individual consultation before starting.

Limitations of This Page

The five studies above are small (34–86 participants), were conducted in different populations, and two of them found no advantage for the combination. The calcaneal spur study is retrospective rather than randomised, and therefore does not carry the evidential weight of a controlled trial. The EMTT evidence base is narrow and includes a declared manufacturer conflict of interest. Nothing here is individual medical advice, and a decision to combine treatments belongs to the treating team. Regulatory clearance is model-specific — ask any supplier for the certificate covering the exact model offered to you, its indication and its expiry date.